Literature DB >> 16801448

Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.

Cornelius J Clancy1, Hong Huang, Shaoji Cheng, Hartmut Derendorf, M Hong Nguyen.   

Abstract

We measured time-kills and postantifungal effects (PAFEs) of caspofungin against Candida albicans, C. parapsilosis, and C. glabrata isolates. One-hour exposure to caspofungin during PAFE experiments accounted for the majority of killing during time-kill experiments. Regrowth of all isolates was inhibited for at least 24 h following drug washout.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16801448      PMCID： PMC1489803          DOI： 10.1128/AAC.00291-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.

Authors:  David Andes
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Echinocandins--an advance in the primary treatment of invasive candidiasis.

Authors:  Thomas J Walsh
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

Review 3.  Echinocandin antifungal drugs.

Authors:  David W Denning
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

4.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

5.  Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.

Authors:  Arnold Louie; Mark Deziel; Weiguo Liu; Michael F Drusano; Tawanda Gumbo; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.

Authors:  Giovanni Di Bonaventura; Ilaria Spedicato; Carla Picciani; Domenico D'Antonio; Raffaele Piccolomini
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

7.  Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.

Authors:  E J Ernst; M E Klepser; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

Authors:  M A Pfaller; D J Diekema; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

9.  A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans.

Authors:  Elias K Manavathu; Mayur S Ramesh; Inthumathi Baskaran; Latha T Ganesan; Pranatharthi H Chandrasekar
Journal:  J Antimicrob Chemother       Date:  2004-01-16       Impact factor: 5.790

10.  Comparison of caspofungin and amphotericin B for invasive candidiasis.

Authors:  Jorge Mora-Duarte; Robert Betts; Coleman Rotstein; Arnaldo Lopes Colombo; Luis Thompson-Moya; Juanita Smietana; Robert Lupinacci; Carole Sable; Nicholas Kartsonis; John Perfect
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245
View more
  28 in total

1.  A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole.

Authors:  Shaoji Cheng; Cornelius J Clancy; Katherine T Nguyen; William Clapp; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

2.  Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum.

Authors:  Ryan K Shields; M Hong Nguyen; Chen Du; Ellen Press; Shaoji Cheng; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

3.  Occidiofungin's chemical stability and in vitro potency against Candida species.

Authors:  Dayna Ellis; Jiten Gosai; Charles Emrick; Rachel Heintz; Lanette Romans; Donna Gordon; Shi-En Lu; Frank Austin; Leif Smith
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

4.  In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.

Authors:  Emilia Cantón; Ana Espinel-Ingroff; Javier Pemán; Lucas del Castillo
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

5.  Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum.

Authors:  Renátó Kovács; Rudolf Gesztelyi; David S Perlin; Gábor Kardos; Marianna Domán; Réka Berényi; László Majoros
Journal:  Mycopathologia       Date:  2014-08-15       Impact factor: 2.574

Review 6.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

7.  Five-minute exposure to caspofungin results in prolonged postantifungal effects and eliminates the paradoxical growth of Candida albicans.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

8.  Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence.

Authors:  Cristina Rueda; Manuel Cuenca-Estrella; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

9.  In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.

Authors:  Emilia Cantón; Javier Pemán; Amparo Valentín; Ana Espinel-Ingroff; Miguel Gobernado
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

10.  Determination of Echinocandin MICs for Candida species in less than 8 hours: comparison of the rapid susceptibility assay with the Clinical and Laboratory Standards Institute's broth microdilution assay.

Authors:  Kevin C Hazen; Dawn Dirks; James Masuoka
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.